drugset
drugset / Trial / NCT04451811

A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers

NCT04451811 ↗

Phase 1 Completed 12 enrolled Oppilan Pharma Ltd Celerion · collab
RandomizedCrossoverOpen-labelOther

Summary

This is a single center, randomized, open-label, three-way crossover, single dose, pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.

Timeline

Start
2020-09-07
Primary completion
2021-02-24
Completion
2021-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject tamuzimod Small molecule 5 mg Oral
Subject tamuzimod Small molecule 20 mg Oral

Indications

No indication recorded.